75/100BSanofi ADS executives and insider trading
Belen Garijo Lopez reported no open-market purchases or sales over the last twelve months.
Over the last twelve months Sanofi ADS's insiders sold 0 shares for 0 USD in 0 sales on the open market, and bought 0 shares in 0 purchases.
Insiders over the last twelve months
- Insider sales
- 0
- Shares sold
- —
- Value sold
- —
- Insider purchasesWhat is insider trading? Insider trading here means the legal trades that a company's executives, directors and large owners make in its shares, reported to the SEC on Form 4.
- 0
Insiders buying against sellingWhat is a Rule 10b5-1 trading plan? A Rule 10b5-1 plan lets an insider fix future trades in advance, while holding no inside information, so later trades follow the plan, not a new decision.
Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).
Executives and directors
The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.
| Name | Position | Age | Shares sold (12 months) | Value sold (12 months) | Shares bought (12 months) | Last sale | Shares held after |
|---|---|---|---|---|---|---|---|
| Belen Garijo Lopez CEO | Chief Executive Officer & Director | 66 | — | — | — | — | — |
| Houman Ashrafian | Executive VP & Head of Research & Development | 51 | — | — | — | — | — |
| Michael Quigley | Chief Scientific Officer & Head of Research | — | — | — | — | — | — |
| Emmanuel Frenehard | Executive VP & Chief Digital Officer | 54 | — | — | — | — | — |
| Olivier Charmeil | Executive Vice President of General Medicines | 63 | — | — | — | — | — |
| Olivier Klaric | Senior Vice President of Financing & Treasury | 64 | — | — | — | — | — |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | 69 | — | — | — | — | — |
| Roy Papatheodorou | Executive Vice President & General Counsel | 48 | — | — | — | — | — |
| Jamie Haney | Executive Vice President & General Counsel | — | — | — | — | — | — |
| Thomas Kudsk Larsen | Head of Investor Relations & General Medicines | 52 | — | — | — | — | — |
| Thomas Triomphe | Executive Vice President of Vaccines | 52 | — | — | — | — | — |
| Veronique Jaillet | Executive VP & Interim Chief People Officer | — | — | — | — | — | — |
| Fabrizio Gaudi | Head of Austrian, German & Swiss Operations | — | — | — | — | — | — |
| Erik Wallström | Head of Therapeutic Area - Neurology Development | — | — | — | — | — | — |
| François-Xavier Roger | Executive Vice President & Chief Financial Officer | 64 | — | — | — | — | — |
Every insider transactionWhat is insider trading? Insider trading here means the legal trades that a company's executives, directors and large owners make in its shares, reported to the SEC on Form 4.
Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.
| Date | Name | Transaction | Shares | Price | Value | Shares held after | Filing |
|---|
Common questions about Sanofi ADS's executives and insiders
Source: Financial Modeling Prep